List of Contents

Recombinant DNA Technology Market Size, Share, and Trends 2024 to 2034

The global recombinant DNA technology market size was USD 803.76 billion in 2023, calculated at USD 856.81 billion in 2024 and is expected to reach around USD 1,623.52 billion by 2034, expanding at a CAGR of 6.6% from 2024 to 2034.

  • Last Updated : August 2024
  • Report Code : 1907
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Recombinant DNA Technology Market 

5.1. COVID-19 Landscape: Recombinant DNA Technology Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Recombinant DNA Technology Market, By Product

8.1. Recombinant DNA Technology Market, by Product, 2024-2034

8.1.1. Medical

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Non-Medical

8.1.2.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Recombinant DNA Technology Market, By Component

9.1. Recombinant DNA Technology Market, by Component e, 2024-2034

9.1.1. Expression System

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Cloning Vector

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.5.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Recombinant DNA Technology Market, By Application 

10.1. Recombinant DNA Technology Market, by Application, 2024-2034

10.1.1. Health and disease

10.1.1.1. Market Revenue and Forecast (2021-2034)

10.1.2. Food and Agriculture

10.1.2.1. Market Revenue and Forecast (2021-2034)

10.1.3. Environment

10.1.3.1. Market Revenue and Forecast (2021-2034)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 11. Global Recombinant DNA Technology Market, By End User 

11.1. Recombinant DNA Technology Market, by End User, 2024-2034

11.1.1. Pharmaceutical and biotechnology companies

11.1.1.1. Market Revenue and Forecast (2021-2034)

11.1.2. Research institutes

11.1.2.1. Market Revenue and Forecast (2021-2034)

11.1.3. Others

11.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 12. Global Recombinant DNA Technology Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Product (2021-2034)

12.1.2. Market Revenue and Forecast, by Component (2021-2034)

12.1.3. Market Revenue and Forecast, by Application (2021-2034)

12.1.4. Market Revenue and Forecast, by End User (2021-2034)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.1.5.2. Market Revenue and Forecast, by Component (2021-2034)

12.1.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.1.5.4. Market Revenue and Forecast, by End User (2021-2034)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Product (2021-2034)

12.1.6.2. Market Revenue and Forecast, by Component (2021-2034)

12.1.6.3. Market Revenue and Forecast, by Application (2021-2034)

12.1.6.4. Market Revenue and Forecast, by End User (2021-2034)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Product (2021-2034)

12.2.2. Market Revenue and Forecast, by Component (2021-2034)

12.2.3. Market Revenue and Forecast, by Application (2021-2034)

12.2.4. Market Revenue and Forecast, by End User (2021-2034)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.2.5.2. Market Revenue and Forecast, by Component (2021-2034)

12.2.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.2.5.4. Market Revenue and Forecast, by End User (2021-2034)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Product (2021-2034)

12.2.6.2. Market Revenue and Forecast, by Component (2021-2034)

12.2.6.3. Market Revenue and Forecast, by Application (2021-2034)

12.2.6.4. Market Revenue and Forecast, by End User (2021-2034)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Product (2021-2034)

12.2.7.2. Market Revenue and Forecast, by Component (2021-2034)

12.2.7.3. Market Revenue and Forecast, by Application (2021-2034)

12.2.7.4. Market Revenue and Forecast, by End User (2021-2034)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Product (2021-2034)

12.2.8.2. Market Revenue and Forecast, by Component (2021-2034)

12.2.8.3. Market Revenue and Forecast, by Application (2021-2034)

12.2.8.4. Market Revenue and Forecast, by End User (2021-2034)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Product (2021-2034)

12.3.2. Market Revenue and Forecast, by Component (2021-2034)

12.3.3. Market Revenue and Forecast, by Application (2021-2034)

12.3.4. Market Revenue and Forecast, by End User (2021-2034)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.3.5.2. Market Revenue and Forecast, by Component (2021-2034)

12.3.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.3.5.4. Market Revenue and Forecast, by End User (2021-2034)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Product (2021-2034)

12.3.6.2. Market Revenue and Forecast, by Component (2021-2034)

12.3.6.3. Market Revenue and Forecast, by Application (2021-2034)

12.3.6.4. Market Revenue and Forecast, by End User (2021-2034)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Product (2021-2034)

12.3.7.2. Market Revenue and Forecast, by Component (2021-2034)

12.3.7.3. Market Revenue and Forecast, by Application (2021-2034)

12.3.7.4. Market Revenue and Forecast, by End User (2021-2034)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Product (2021-2034)

12.3.8.2. Market Revenue and Forecast, by Component (2021-2034)

12.3.8.3. Market Revenue and Forecast, by Application (2021-2034)

12.3.8.4. Market Revenue and Forecast, by End User (2021-2034)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Product (2021-2034)

12.4.2. Market Revenue and Forecast, by Component (2021-2034)

12.4.3. Market Revenue and Forecast, by Application (2021-2034)

12.4.4. Market Revenue and Forecast, by End User (2021-2034)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.4.5.2. Market Revenue and Forecast, by Component (2021-2034)

12.4.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.4.5.4. Market Revenue and Forecast, by End User (2021-2034)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Product (2021-2034)

12.4.6.2. Market Revenue and Forecast, by Component (2021-2034)

12.4.6.3. Market Revenue and Forecast, by Application (2021-2034)

12.4.6.4. Market Revenue and Forecast, by End User (2021-2034)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Product (2021-2034)

12.4.7.2. Market Revenue and Forecast, by Component (2021-2034)

12.4.7.3. Market Revenue and Forecast, by Application (2021-2034)

12.4.7.4. Market Revenue and Forecast, by End User (2021-2034)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Product (2021-2034)

12.4.8.2. Market Revenue and Forecast, by Component (2021-2034)

12.4.8.3. Market Revenue and Forecast, by Application (2021-2034)

12.4.8.4. Market Revenue and Forecast, by End User (2021-2034)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.5.2. Market Revenue and Forecast, by Component (2021-2034)

12.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.5.4. Market Revenue and Forecast, by End User (2021-2034)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.5.5.2. Market Revenue and Forecast, by Component (2021-2034)

12.5.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.5.5.4. Market Revenue and Forecast, by End User (2021-2034)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Product (2021-2034)

12.5.6.2. Market Revenue and Forecast, by Component (2021-2034)

12.5.6.3. Market Revenue and Forecast, by Application (2021-2034)

12.5.6.4. Market Revenue and Forecast, by End User (2021-2034)

Chapter 13. Company Profiles

13.1. Pfizer

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Sanofi

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. New England Biolabs

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. GlaxoSmithKline plc

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. GenScript

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Thermo Fisher Scientific, Inc

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Biogen, Inc

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Merck & Co., Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Profacgen

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Amgen, Inc

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client